Today: 20 January 2026
Subscribe
Browse Category

Drug Pricing News 2 January 2026 - 13 January 2026

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

New York, January 13, 2026, 14:45 ET — Regular session AbbVie shares slipped 0.1% to $219.83 Tuesday afternoon after the drugmaker announced a three-year deal with the Trump administration. The pact aims to lower certain drug prices in return for exemptions from tariffs and future pricing rules. The deal arrives amid investor attempts to figure out how “lower prices” might…
13 January 2026
····
Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

New York, Jan 11, 2026, 10:45 EST — Market closed. Shares of Johnson & Johnson (JNJ.N) dipped 0.7% on Friday to $204.39 following the company’s announcement of a deal with the Trump administration to lower U.S. drug prices. In return, J&J secured exemptions from certain U.S. tariffs. The company said it will offer medicines at discounted rates via TrumpRx.gov and…
11 January 2026
····
Johnson & Johnson stock dips on Trump drug-price deal — what to watch before Monday

Johnson & Johnson stock dips on Trump drug-price deal — what to watch before Monday

New York, January 10, 2026, 10:58 ET — Market closed Johnson & Johnson shares fell 0.7% on Friday, closing at $204.39. The company said it reached an agreement with the U.S. government to lower drug prices in exchange for exemptions from tariffs. (Reuters) The timing matters: drugmakers are heading into another round of pricing battles abroad, particularly in Europe, after…
10 January 2026
···
Johnson & Johnson stock slips on Trump drug-price pact as tariff relief comes into view

Johnson & Johnson stock slips on Trump drug-price pact as tariff relief comes into view

New York, Jan 9, 2026, 14:40 (EST) — Regular session Johnson & Johnson shares slipped about 0.5% to $204.76 on Friday after the company said it struck an agreement with President Donald Trump’s administration to lower drug prices for Americans in return for exemptions from U.S. tariffs. Johnson & Johnson did not say which medicines are included or how large…
9 January 2026
··
Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

New York, Jan 8, 2026, 10:13 EST — Regular session Pfizer Inc shares rose 0.3% to $25.36 on Thursday after a U.S. appeals court blocked a Trump administration pilot that would have changed how safety-net hospitals pay for some medicines. The program covered the first 10 drugs heading into Medicare price negotiations, including Pfizer and Bristol Myers Squibb’s blood thinner…
8 January 2026
···
Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

NEW YORK, Jan 8, 2026, 08:59 (EST) — Premarket Omeros Corp (OMER.O) shares were up 0.55, or about 4%, at $14.09 in premarket trade on Thursday after the drugmaker set a $36,000 price for each single-dose vial of its newly approved Yartemlea treatment for transplant-associated thrombotic microangiopathy (TA-TMA). “Median utilization was 8 to 10 vials per treatment course,” Chief Executive…
8 January 2026
····
Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

New York, Jan 6, 2026, 10:40 EST — Regular session Novo Nordisk A/S shares listed in New York as ADRs climbed about 4.7% to $57.71 on Tuesday, after touching an intraday high of $58.14. The move extends a rebound sparked by the U.S. rollout of a pill version of Wegovy, a franchise that has become central to how investors value…
6 January 2026
····
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

New York, January 5, 2026, 14:21 EST — Regular session Shares of Viking Therapeutics (VKTX) slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%. The move highlights how…
5 January 2026
···
Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

New York, January 5, 2026, 10:58 (ET) — Regular session Eli Lilly and Company shares fell about 3.4% on Monday, extending early losses after rival Novo Nordisk began selling a pill version of its Wegovy weight-loss drug in the United States. The stock was down at $1,043.14 after dipping nearly 4% earlier in the session. The move puts the spotlight…
5 January 2026
···
Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

NEW YORK, January 3, 2026, 10:33 ET — Market closed Eli Lilly and Company shares closed up 0.53% at $1,080.36 on Friday and were down 0.17% in after-hours trading at $1,078.50. The move matters because early January is when many drugmakers reset “list prices” — the published prices before rebates and insurer discounts — and those changes can shape negotiations…
3 January 2026
····
AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

NEW YORK, Jan 2, 2026, 14:08 ET — Regular session AbbVie shares ticked higher on Friday after Ironwood Pharmaceuticals, its partner on constipation drug Linzess, raised its 2026 outlook and said it lowered the medicine’s list price at the start of the year. The update matters because Linzess is co-developed and co-commercialized with AbbVie in the U.S., and changes in…
2 January 2026
···
Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

NEW YORK, January 2, 2026, 13:56 ET — Regular session Pfizer Inc shares rose 0.8% to $25.09 on Friday, as investors digested renewed attention on U.S. drug pricing and early-year list-price changes. The timing matters. January is when drugmakers typically reset U.S. prices, and the moves can quickly become a political and regulatory flashpoint — especially as the Trump administration…
2 January 2026
····
1 2 3 4

Stock Market Today

  • Micron and Arista Networks Lead 2026 AI Stock Rally Amid Taiwan Semiconductor's Capex Surge
    January 20, 2026, 8:32 AM EST. AI stocks surged in early 2026, lifted by Taiwan Semiconductor's strong Q4 results and increased capital expenditure guidance. The chipmaker raised its 2026 capex to $52-$56 billion, up from $40.9 billion in 2025, signaling sustained growth in AI infrastructure spending. Investors should consider leading AI stocks like Micron Technology (Zacks Rank #1) and Arista Networks (Zacks Rank #2) for long-term gains. Micron, a major memory chip maker, projects a 95% revenue increase in fiscal 2026, benefiting from demand for high-bandwidth memory vital to AI workloads. Arista, a data center networking firm serving clients like Meta, stands to gain from the booming AI data center sector, with global AI infrastructure spending expected to approach $7 trillion by 2030. The tech sector's earnings outlook and overall economy show broad growth prospects.
Go toTop